XML 41 R21.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Product Revenue | 12 Months Ended
--- | ---
Dec. 31, 2024
Revenue from Contract with Customer [Abstract] |
Product Revenue | Product Revenue The Company’s product revenue is primarily derived from the sale of its internally developed products BRUKINSA and TEVIMBRA in the U.S., China, and other regions; XGEVA, BLINCYTO and KYPROLIS in China under a license from Amgen; REVLIMID® and VIDAZA® in China under a license from BMS; and POBEVCY® in China under a license from Bio-Thera. The table below presents the Company’s net product sales for the years ended December 31, 2024, 2023 and 2022.
| Year Ended December 31,
| 2024 |  | 2023 |  | 2022
| $ |  | $ |  | $
Product revenue - gross | 4,786,744 |  |  | 2,718,969 |  |  | 1,438,440 |
Less: Rebates and sales returns | (1,007,198) |  |  | (529,117) |  |  | (183,828) |
Product revenue - net | 3,779,546 |  |  | 2,189,852 |  |  | 1,254,612 |
The following table disaggregates net product revenue by product for the years ended December 31, 2024, 2023 and 2022.
| Year Ended December 31,
| 2024 |  | 2023 |  | 2022
| $ |  | $ |  | $
BRUKINSA® | 2,644,226 |  |  | 1,290,396 |  |  | 564,651 |
Tislelizumab | 620,836 |  |  | 536,620 |  |  | 422,885 |
XGEVA® | 224,403 |  |  | 92,828 |  |  | 63,398 |
BLINCYTO® | 74,331 |  |  | 54,342 |  |  | 36,107 |
KYPROLIS® | 66,171 |  |  | 39,799 |  |  | 13,696 |
POBEVCY® | 53,509 |  |  | 56,547 |  |  | 38,124 |
REVLIMID® | 36,028 |  |  | 76,018 |  |  | 79,049 |
Other | 60,042 |  |  | 43,302 |  |  | 36,702 |
Total product revenue - net | 3,779,546 |  |  | 2,189,852 |  |  | 1,254,612 |
The following table presents the roll-forward of accrued sales chargebacks, rebates, returns and other deductions for the years ended December 31, 2024 and 2023.
| Rebates, Returns and Other Deductions |  | Contra AR Accruals |  | Total
| $ |  | $ |  |
Balance at December 31, 2022 | 41,817 |  |  | 8,580 |  |  | 50,397 |
Amounts charged against product revenue | 275,031 |  |  | 254,086 |  |  | 529,117 |
Payments and credits | (176,912) |  |  | (232,231) |  |  | (409,143) |
Balance at December 31, 2023 | 139,936 |  |  | 30,435 |  |  | 170,371 |
Amounts charged against product revenue | 491,756 |  |  | 515,442 |  |  | 1,007,198 |
Payments and credits | (396,092) |  |  | (495,178) |  |  | (891,270) |
Balance at December 31, 2024 | 235,600 |  |  | 50,699 |  |  | 286,299 |

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration